Healthcare Industry News: Gamma Knife
News Release - August 1, 2013
Elekta to Exhibit New Versa HD Radiotherapy System at Annual Radiation Physics ConferenceFirst showing of breakthrough linear accelerator at 2013 American Association of Physicists in Medicine (AAPM) Annual Meeting
INDIANAPOLIS, Aug. 1, 2013 -- (Healthcare Sales & Marketing Network) -- AAPM Booth #409 – Elekta's Versa HD™* will make its AAPM debut at the association's 55th Annual Meeting and Exhibition, August 4-8 at Indianapolis's Indiana Convention Center. It will be the first time that Elekta showcases Versa HD at a scientific conference in the U.S. since the system's worldwide introduction on March 1. The high-definition Agility™ beam shaping and High Dose Rate mode of Versa HD give clinicians the flexibility to deliver conventional therapies to treat a wide range of small and large tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.
Elekta's theme for AAPM is The Power of Care, a concept that includes technology and people working together to support positive patient outcomes. Versa HD reinforces this new standard of care through its flexibility, speed and accuracy, in addition to a series of packages designed to address unique clinical challenges, making it easy to customize a system that meets the needs of both clinics and patients. Available with Versa HD are packages for spine, breast, prostate, head & neck, and lung.
Other exhibition highlights include:
Clarity® Autoscan – Real-time soft tissue tracking for motion during treatment
MOSAIQ® Mobile** – Instant access to MOSAIQ from anywhere
Flexitron® afterloading platform – Optimized treatment delivery process for brachytherapy
Leksell GammaPlan® – Gamma Knife® treatment planning system that offers unmatched speed and accuracy
Customer events during AAPM
On Monday, August 5 at the Westin Indianapolis, Elekta will host a complimentary customer luncheon on the use of Leksell Gamma Knife and GammaPlan. All are welcome to join and earn MPCEC credits through CAMPEP.
On Tuesday, August 6 at the Westin Indianapolis, Elekta will hold a complimentary customer luncheon that will highlight specific planning considerations when using Monaco® treatment planning system with Agility 160-leaf multileaf collimator (MLC). The presentation will be given by Lennart Jahnke, PhD, Clinic for Radiation Oncology, Medical University of Mannheim.
During the same session, Jens Fleckenstein, PhD, Clinic for Radiation Oncology, Medical University of Mannheim, will give a presentation titled, "Clinical Experiences with FFF Treatment Delivery."
Register online at www.elekta.com/AAPM.
*Versa HD is not for sale or distribution in all markets.
**MOSAIQ Mobile is a work in progress and not for sale in all markets.
For further information, please contact
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.